BioXp™ 9600 system – a fully automated, high-throughput benchtop instrument for synthetic biology workflows – empowers scientists to accelerate discovery of new vaccines and biologics
The fully automated BioXp™ system enables scientists to overcome process limitations created by the turnaround time, cost, or complexity of alternative means of building or acquiring DNA and mRNA. The BioXp™ system provides over-night, automated synthesis of genes, clones, DNA libraries, and mRNA, enabling users to more tightly integrate design and build cycles, driving greater productivity and reducing time to answer.
“Codex DNA is committed to empowering and inspiring scientists to advance their discovery of life-changing vaccines and biologics. We believe the BioXp™ 9600 system, the third release on our versatile and powerful BioXp platform, can enable scientists to overcome inefficiencies in their workflows which limit their discovery. Demonstrating our commitment, we accelerated development of this system, releasing one quarter ahead of schedule,” said
“The versatility of the platform enables us to release additional capabilities intended to optimize discovery workflows. Beginning in Q1 of 2023 we will release additional BioXp kits that enable scientists to begin the cloning, amplification, and mRNA synthesis process from the customers own linear DNA or plasmid DNA. We believe providing scientists the flexibility to begin with their sequence, linear DNA, or plasmid DNA, will further expand the utility, speed, and impact of the system,” said
About
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on Codex DNA’s beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause Codex DNA’s actual results, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements. These and other risks are described more fully in Codex DNA’s filings with the
Media Contact:
Sr. Director of Marketing
charlie@codexdna.com
© OMX, source